Abstract
Transition to non-active secondary progressive multiple sclerosis (SPMS) after up to 9.5 years of natalizumab treatment in the real-world TYSABRI Observational Program (TOP) (2802)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
